Acuitas co-founder Pieter Cullis on breakthrough vaccine innovation
BIV Today
English - May 10, 2021 21:39 - 23 minutes - 21.8 MBEntrepreneurship Business News Business News Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Diving into B.C.'s employment contraction
Next Episode: EDI on BIV: Why women-centric programs don't work
A made-in-B.C. innovation is playing a critical role in the Pfizer-BioNTech COVID-19 vaccine rolling out across the globe. Lipid nanoparticle technology — or LNP — developed by Vancouver’s Acuitas Therapeutics is one of the key factors allowing the vaccine to work. Acuitas co-founder Pieter Cullis joins BIV Today to break it down. Tyler Orton hosts.
See omnystudio.com/listener for privacy information.